Schedule of enrolment, treatments and assessments
| Enrolment and baseline | CIPN Screening | Randomisation | Intervention period | Follow-up period week 8 | Follow-up period week 24 | |
| Time point | −t1 | Weekly at infusion (0) | After CIPN symptom onset (0) | Weekly for 10 weeks (t1 – t10) | t10+8 w (± 2 weeks) | t10+24 w (± 2 weeks) |
| Enrolment: | ||||||
| Eligibility screen | X | |||||
| Informed consent | X | |||||
| Allocation | X | |||||
| Interventions: | ||||||
| Electroacupuncture | X | |||||
| Sham-electroacupuncture | X | |||||
| Assessments: | ||||||
| ESAS 17 | X | X | ||||
| EORTC QLQ-CIPN20 | X | X | X | X | ||
| Patient feedback form | X (t10) | |||||
| AES | X | X (t5 + t10) | ||||
| Concomitant CIPN treatments | X | X | X | X |
AES, Acupuncture Expectancy Scale; CIPN, chemotherapy-induced peripheral neuropathy; EA, electroacupuncture; EORTC QLQ-CIPN20, European Organisation for Research and Treatment of Cancer Quality of Life Chemotherapy-Induced Peripheral Neuropathy 20; ESAS 17, Edmonton Symptom Assessment Scale 17; X, required.